**Author’s response to reviews**

**Title:** A newly developed oxime K203 is the most effective reactivator of tabun-inhibited acetylcholinesterase

**Authors:**

Kamil Kuca (kamil.kuca@uhk.cz)

Kamil Musilek (kamil.musilek@uhk.cz)

Daniel Jun (daniel.jun@unob.cz)

Jana Zdarova-karasova (jana.zdarova@unob.cz)

Eugenie Nepovimova (eugenie.nepovimova@uhk.cz)

Ondrej Soukup (ondrej.soukup@fnhk.cz)

Martina Hrabinova (martina.hrabinova@unob.cz)

John Mikler (john.mikler@drdc-rddc.gc.ca)

Tanos Franca (tanos@ime.eb.br)

Elaine F. F. DA CUNHA (elaine_cunha@dqi.ufla.br)

Alexandre A. De Castro (teo@dqi.ufla.br)

Martin Valis (martin.valis@fnhk.cz)

Teodorico Ramalho (teodorico.ramalho@gmail.com)

**Version:** 3 **Date:** 01 Jan 2018

**Author’s response to reviews:**

Response Letter:

1. **TEXTUAL OVERLAP:**

We note that the current submission contains some textual overlap with other previously published works, in particular:
"Molecular Docking, Metal Substitution and Hydrolysis Reaction of Chiral Substrates of Phosphotriesterase" (2016) Combinatorial Chemistry & High Throughput Screening, https://doi.org/10.2174/1386207319666160325113844

and


This overlap mainly exists in the Methodology and Discussion section (when talking about docking studies).

While we understand that you may wish to express some of the same ideas contained in these publications, please be aware that we cannot condone the use of text from previously published work. Please re-phrase these sections to minimise overlap.

Answer: Thank you so much for your comment. In order to meet the requirements, a careful revision was made in these sections in order to minimize overlap.

2. TITLE PAGE:

Please include a title page as the first page of your manuscript where you list the full names, institutional addresses and email addresses for all authors. The corresponding author should be indicated

Answer: All authors together with affiliations were added on the title page. Kamil Kuca as corresponding author was highlighted.
3. ABSTRACT:

As per our submission guidelines, please format the abstract so it contains the following subsections: *Background. *Methods. *Results. *Conclusions.

Answer: Abstract was formatted as requested.

4. FIGURES:

a. Figures should only be provided as separate files, and each figure of a manuscript should be submitted as a single file.

b. Please ensure the figure files are in order.

c. Please provide figure titles/legends under a separate heading of Figure Legends after the References. If Figure titles/legends are within the main text of the manuscript, please move them. If titles/legends are present within the figure files, please remove them.

Answer: Thank you for your suggestion. In the present version, figures are provided as separate files (in order), and the section ‘Figure Legends’ was added to manuscript. The figure legends within the main text were moved.

5. TABLES:

We note that you have included your tables in the manuscript and have uploaded them as separate table files. Please only provide one copy of each table and remove either the tables in the manuscript or the supplementary table files.

Answer: Thank you so much for your comment. One copy of each table was provided as separate files. The section ‘Table Legends’ was added to manuscript.
6. HEADINGS:
   a. Please remove the numbers from the headings.
   
b. Please change ŒIntroduction¹ to ŒBackground¹
   
   Answer: Done.

7. ETHICS APPROVAL:

   Please explicitly state whether the ethics committee approved the study protocols. The current statement that the study was done in accordance with the ethics committee is a bit too unclear. If the need for ethics approval was not necessary, please provide a justification for this.

   Answer: Thank you for your suggestion. It was really unclear. It was replaced by clear statement that Experiments were approved by the Ethics Committee of the Faculty of Military Health Sciences in Hradec Kralove (Czech Republic).

8. CONSENT TO PUBLISH:

   Please amend the statement in the "Consent for publication" section, as this refers to consent obtained to publish potentially-identifying information (of patients/participants). Seeing as this is not applicable to your study, please write ŒNot applicable¹.

   Answer: Thank you for your suggestion. We did so.
9. AVAILABILITY OF DATA AND MATERIALS:

Please indicate how readers can obtain the raw data. An acceptable statement would be the following: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Answer: Thank you for your suggestion. We did so.

10. MISSING DECLARATIONS:

As per our editorial policies, please include Competing Interests and Acknowledgements headings in the Declarations section.

Answer: Thank you for your suggestion. We did so.

11. Clean manuscript: We note that throughout your manuscript, and in your figures and tables, there is highlighted text. At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files.

Answer: Thank you for your suggestion. We did so.

12. English was checked by native speaker.